MLKL and Alzheimer disease: Emerging evidence indicates that necroptosis is markedly activated in the brains of AD patients, characterized by increased expression of key necroptosis proteins RIPK1 and MLKL, leading to decreased neuronal survival and brain volume (Jayaraman et al., 2021).